GlassScriptPhysician profile
Catherine G Fuller
NPI 1851349120
$7,345.72
in general payments reported to CMS, 2019-2025
35 companies · $1,133 in 2025
The $1,133 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $708 · 2020: $626 · 2021: $1,190 · 2022: $1,534 · 2023: $1,368 · 2024: $786 · 2025: $1,133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,282 · Education: $5.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,282.10 |
| Education | $5.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,237.43 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $926.40 | 2019-2025 | Fasenra, Breztri, Tezspire |
| Regeneron Healthcare Solutions, INC. | $692.53 | 2020-2025 | Dupixent |
| Genzyme Corporation | $596.53 | 2021-2025 | |
| Amgen INC. | $453.91 | 2021-2025 | Tezspire |
| Pfizer INC. | $388.98 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $376.02 | 2020-2025 | Cuvitru |
| Novartis Pharmaceuticals Corporation | $333.39 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $321.97 | 2019-2024 | Spiriva Respimat |
| Genentech USA, INC. | $242.30 | 2019-2025 | Xolair |
| Csl Behring | $223.90 | 2019-2025 | Hizentra |
| Octapharma USA, INC. | $211.15 | 2019-2023 | Panzyga |
| Optinose US, INC. | $154.46 | 2019-2025 | |
| Alk-Abello, INC | $142.69 | 2019-2025 | Grastek, Ragwitek, Odactra |
| Teva Pharmaceuticals USA, INC. | $137.26 | 2019-2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blueprint Medicines Corporation | $113.02 | 2023-2025 | Ayvakit |
| Biocryst US Sales Co., LLC | $97.84 | 2022-2025 | Orladeyo |
| Abbvie INC. | $95.26 | 2022-2024 | |
| Kaleo, INC. | $78.16 | 2022 | |
| Pharming Healthcare, INC. | $77.56 | 2019-2024 | Ruconest |
| Incyte Corporation | $55.37 | 2024-2025 | Opzelura |
| Ars Pharmaceuticals Operations, INC. | $50.95 | 2025 | Neffy |
| Horizon Therapeutics Plc | $41.97 | 2019 | |
| Phadia US INC. | $38.26 | 2022-2024 | Immunocap |
| Regeneron Pharmaceuticals, INC. | $33.28 | 2025 | Dupixent |
| Eyevance Pharmaceuticals LLC | $32.70 | 2021 | |
| Galderma Laboratories, L.P. | $29.18 | 2025 | Nemluvio |
| Lilly USA, LLC | $26.41 | 2025 | Ebglyss |
| Hikma Pharmaceuticals USA | $24.52 | 2025 | Ryaltris |
| Bio Products Laboratory USA, INC. | $21.61 | 2021 | |
| Shire North American Group INC | $20.81 | 2019 | |
| Merck Sharp & Dohme LLC | $18.93 | 2021 | |
| Arcutis Biotherapeutics, INC. | $18.00 | 2025 | Zoryve |
| Grifols USA, LLC | $17.80 | 2020 | |
| Aimmune Therapeutics, INC. | $15.17 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Fuller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.